Loading clinical trials...
Loading clinical trials...
Comparison of Decolonization of MRSA Using Theraworx
The purpose of this study is to examine treatment method of Methicillin-resistant Staphylococcus aureus (MRSA) decolonization in patients.
Decolonization therapy is indicated for management of patients with MRSA. Theraworx is reported to be an effective antimicrobial against multiple organisms. In this study, patients with positive MRSA colonization culture will be treated with Theraworx to evaluate decolonization duration capability.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
Yes
Start Date
March 1, 2008
Primary Completion Date
February 1, 2009
Completion Date
February 1, 2009
Last Updated
March 23, 2017
Theraworx
OTHER
mupirocin antibiotic ointment
DRUG
Lead Sponsor
Mercy Research
NCT05632315
NCT04171817
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions